Albert Labs (CSE: ABRT) is a bio-pharmaceutical company pursuing licensing approval for active compounds from natural sources; providing access to effective prescription medicines for people suffering from mental health disorders. Our team of drug development experts leverage advanced culture technology and extraction methods to produce unique and effective natural medicines. We develop clinical solutions through an approved, fast track regulatory pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognized clinical access route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines. Through collaborations with research institutions, hospital centres and government agencies, we utilise existing clinical infrastructure to deliver and improve patient access to their treatment. Our first drug target, KRN-101 for a potential solution for cancer-related anxiety, will support an initial market of over 15 million people with an estimated 1 million new sufferers each year.